Dowling & Yahnke’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $8.95M | Buy |
204,469
+523
| +0.3% | +$25.4K | 0.42% | 56 |
|
|
2022
Q2 | $10.7M | Sell |
203,946
-1,495
| -0.7% | -$76.2K | 0.5% | 45 |
|
|
2022
Q1 | $10.6M | Sell |
205,441
-9,272
| -4% | -$481K | 0.46% | 56 |
|
|
2021
Q4 | $12.7M | Sell |
214,713
-2,781
| -1% | -$138K | 0.61% | 38 |
|
|
2021
Q3 | $9.35M | Buy |
217,494
+1,154
| +0.5% | +$51.1K | 0.52% | 56 |
|
|
2021
Q2 | $8.47M | Buy |
216,340
+2,623
| +1% | +$102K | 0.49% | 69 |
|
|
2021
Q1 | $7.74M | Sell |
213,717
-3,447
| -2% | -$122K | 0.53% | 60 |
|
|
2020
Q4 | $7.99M | Buy |
217,164
+8,929
| +4% | +$328K | 0.57% | 51 |
|
|
2020
Q3 | $7.25M | Buy |
208,235
+4,539
| +2% | +$159K | 0.58% | 52 |
|
|
2020
Q2 | $6.32M | Buy |
203,696
+7,097
| +4% | +$241K | 0.53% | 57 |
|
|
2020
Q1 | $6.09M | Sell |
196,599
-15,431
| -7% | -$526K | 0.59% | 52 |
|
|
2019
Q4 | $7.88M | Sell |
212,030
-10,099
| -5% | -$360K | 0.61% | 51 |
|
|
2019
Q3 | $7.57M | Sell |
222,129
-89
| -0% | -$3.24K | 0.63% | 50 |
|
|
2019
Q2 | $9.13M | Buy |
222,218
+3,122
| +1% | +$124K | 0.76% | 34 |
|
|
2019
Q1 | $8.83M | Buy |
219,096
+7,336
| +3% | +$294K | 0.85% | 31 |
|
|
2018
Q4 | $9.29M | Buy |
211,760
+3,411
| +2% | +$142K | 0.96% | 30 |
|
|
2018
Q3 | $8.71M | Sell |
208,349
-3,314
| -2% | -$128K | 0.76% | 33 |
|
|
2018
Q2 | $7.29M | Sell |
211,663
-2,610
| -1% | -$89.2K | 0.68% | 41 |
|
|
2018
Q1 | $7.21M | Sell |
214,273
-3,534
| -2% | -$121K | 0.68% | 41 |
|
|
2017
Q4 | $7.49M | Sell |
217,807
-1,019
| -0.5% | -$34.7K | 0.68% | 43 |
|
|
2017
Q3 | $7.41M | Sell |
218,826
-5,333
| -2% | -$171K | 0.75% | 34 |
|
|
2017
Q2 | $7.14M | Sell |
224,159
-235
| -0.1% | -$7.41K | 0.75% | 35 |
|
|
2017
Q1 | $7.28M | Sell |
224,394
-1,420
| -0.6% | -$44.8K | 0.78% | 31 |
|
|
2016
Q4 | $6.96M | Buy |
225,814
+1,734
| +0.8% | +$52.9K | 0.78% | 31 |
|
|
2016
Q3 | $7.2M | Buy |
224,080
+1,897
| +0.9% | +$63.4K | 0.84% | 27 |
|
|
2016
Q2 | $7.42M | Buy |
222,183
+1,688
| +0.8% | +$53.9K | 0.89% | 25 |
|
|
2016
Q1 | $6.2M | Buy |
220,495
+8,530
| +4% | +$244K | 0.77% | 35 |
|
|
2015
Q4 | $6.49M | Sell |
211,965
-3,171
| -1% | -$99.8K | 0.82% | 31 |
|
|
2015
Q3 | $6.41M | Buy |
215,136
+4,331
| +2% | +$139K | 0.87% | 25 |
|
|
2015
Q2 | $6.71M | Buy |
210,805
+133
| +0.1% | +$4.33K | 0.84% | 25 |
|
|
2015
Q1 | $6.95M | Buy |
210,672
+512
| +0.2% | +$16.3K | 0.87% | 22 |
|
|
2014
Q4 | $6.21M | Buy |
210,160
+21
| +0% | +$602 | 0.77% | 32 |
|
|
2014
Q3 | $5.89M | Sell |
210,139
-7,970
| -4% | -$224K | 0.78% | 30 |
|
|
2014
Q2 | $6.14M | Sell |
218,109
-3,057
| -1% | -$87.1K | 0.79% | 30 |
|
|
2014
Q1 | $6.74M | Buy |
221,166
+301
| +0.1% | +$8.97K | 0.89% | 22 |
|
|
2013
Q4 | $6.42M | Buy |
220,865
+20,943
| +10% | +$610K | 0.9% | 23 |
|
|
2013
Q3 | $5.45M | Buy |
+199,922
| New | +$5.44M | 0.85% | 26 |
|
Other funds holding PFE
Dowling & Yahnke's PFE Position: Q3 2022 in Review
Dowling & Yahnke increased its Pfizer (PFE) stake by 0.26% in Q3 2022, buying an estimated $25.4K and bringing the position to 204,469 shares worth $8.95M. The position accounts for 0.42% of the portfolio, ranked #56.
Dowling & Yahnke first reported a position in PFE in Q3 2013 and has held it in 37 quarters since. The position peaked at $12.7M in Q4 2021. 3,086 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Dowling & Yahnke held 204,469 shares of Pfizer worth $8.95M as of Q3 2022.
- Dowling & Yahnke bought 523 Pfizer shares in Q3 2022, an estimated $25.4K.
- Pfizer made up 0.42% of Dowling & Yahnke's portfolio in Q3 2022, its #56 holding.
- Dowling & Yahnke first reported a position in Pfizer in Q3 2013 and has held it in 37 quarters since.
- Dowling & Yahnke's Pfizer position peaked at $12.7M in Q4 2021.
- 3,086 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.